“…However, in developing countries and in some developed countries, these therapeutic options are expensive, and not readily accessible, especially to the poor (Adeneye and Agbaje, 2008). Aside these, the therapeutic regimen are considered rigid, multipharmaceutical, and often associated with intolerable side effects (Adeneye and Agbaje, 2008).…”